QL2106
/ Qilu Pharma
- LARVOL DELTA
Home
Next
Prev
1 to 1
Of
1
Go to page
1
March 18, 2026
A Comparative Phase 1 Study to Evaluate the Pharmacokinetic and Safety of QL2106 vs Tremfye® in Healthy Subjects
(clinicaltrials.gov)
- P1 | N=190 | Active, not recruiting | Sponsor: Qilu Pharmaceutical Co., Ltd.
New P1 trial
1 to 1
Of
1
Go to page
1